NCT07935941
A Phase I Study of HLX109 in Healthy Participants
StatusNot Yet Recruiting
PhasePhase 1
SponsorShanghai Henlius Biotech
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Safety: number and percentage of participants with adverse events (AEs) assessed by CTCAE v6.0
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with serious adverse events (SAEs) assessed by CTCAE v6.0
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with adverse events of special interest (AESIs) assessed by CTCAE v6.0
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with laboratory abnormalities
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with notable 12-Lead electrocardiogram (ECG) values
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with clinically notable vital signs
Timeframe: Up to approximately 84 days
Secondary (13)
PK: peak concentration (Cmax)
PK: area under the concentration-time curve (AUC0-t, AUC0-inf)
PK: time to peak concentration (Tmax)
PK: terminal elimination half-life (t1/2)
PK: apparent clearance (CL/F)
Show 8 moreShow less
PK: apparent volume of distribution (Vz/F)
PK: mean residence time (MRT)
PK: percentage of extrapolated AUC (%AUCex)
Immunogenicity: incidence of anti-drug antibody (ADA) against HLX109 and recombinant human hyaluronidase.
Immunogenicity: incidence of neutralizing antibody (NAb) against HLX109 and recombinant human hyaluronidase.
Exploratory: serum free/total soluble IL-1RAP (sIL-1RAP) levels
Exploratory: ex vivo stimulated cytokine release levels in whole peripheral blood
Exploratory: IL-1RAP receptor occupancy (RO)
Arms and interventions
HLX109Experimental
Dose Escalation
PlaceboPlacebo comparator
Dose Escalation
Drugs: HLX109, Placebo
Sites
2 sites in 2 countries
Australia 1, China 1